Revolution Medicines
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 378
- Market Cap
- $7.2B
- Website
- http://www.revmed.com
- Introduction
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)
- Conditions
- NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT06881784
- Locations
- 🇺🇸
Cleveland Clinic Martin North, Stuart, Florida, United States
🇺🇸TriHealth Cancer & Blood Institute Research, Cincinnati, Ohio, United States
🇺🇸BRCR Global, Plantation, Florida, United States
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Conditions
- Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06625320
- Locations
- 🇺🇸
City of Hope-Duarte, Duarte, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Conditions
- PDACCRCPancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaColorectal CancerGastrointestinal Cancer
- Interventions
- Drug: mFOLFOX6 regimenDrug: mFOLFIRINOX regimen
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 1130
- Registration Number
- NCT06445062
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸UCLA Hematology/Oncology- Santa Monica, Los Angeles, California, United States
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Conditions
- Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung CancerLung Cancer Stage IV, Advanced Solid Tumor, CancerRAS G12D-mutated NSCLC
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 616
- Registration Number
- NCT06162221
- Locations
- 🇺🇸
City of Hope - Duarte, Duarte, California, United States
🇺🇸City of Hope - Lennar, Irvine, California, United States
🇺🇸UC Davis, Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Conditions
- Colorectal CancerPancreatic Ductal AdenocarcinomaNon-Small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Assigned interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06128551
- Locations
- 🇮🇹
Niguarda Cancer Center, Milano, Italy
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC IRVINE Health, Orange, California, United States
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 444
- Registration Number
- NCT06040541
- Locations
- 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Smilow Cancer Hospital (Yale University), New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
- Conditions
- Advanced Solid TumorNon-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT05462717
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UC Irvine Cancer Center, Orange, California, United States
🇺🇸UC Davis Cancer Center, Sacramento, California, United States
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Advanced Solid Tumors
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 614
- Registration Number
- NCT05379985
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UCLA, Santa Monica, California, United States
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05054725
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Cancer Specialists of North Florida, Saint Augustine, Florida, United States
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT04774952
- Locations
- 🇺🇸
UC Irvine - Chao Family Comprehensive Cancer Center, Irvine, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸UC San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States